Barclays’s CERo Therapeutics CERO Stock Holding History

Barclays’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5	Closed	-$74	–	5598
2025 Q1	$74	Buy	+5	New	+$198	﹤0.01%	5135
2023 Q1	–	Sell	-53	Closed	-$1.09M	–	5403
2022 Q4	$1.09M	Hold	53	–	–	﹤0.01%	2719
2022 Q3	$1.07M	Hold	53	–	–	﹤0.01%	2177
2022 Q2	$1.06M	Hold	53	–	–	﹤0.01%	2299
2022 Q1	$1.06M	Buy	+53	New	+$1.05M	﹤0.01%	2348

Other funds holding CERO

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays's CERO Position: Q2 2025 in Review

Barclays sold out of CERo Therapeutics (CERO) in Q2 2025, closing a stake of 5 shares — an estimated $74 sold.

Barclays first reported a position in CERO in Q1 2022 and held it in 5 quarters. The position peaked at $1.09M in Q4 2022. 8 funds tracked by Wall St. Rank hold CERO as of Q2 2025.

Barclays reported no remaining CERo Therapeutics position as of Q2 2025 after selling out during the quarter.
Barclays sold 5 CERo Therapeutics shares in Q2 2025, an estimated $74.
Barclays first reported a position in CERo Therapeutics in Q1 2022 and held it in 5 quarters.
Barclays's CERo Therapeutics position peaked at $1.09M in Q4 2022.
8 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.